Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 14/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23055428 | 0.85 | KDM4E (0.36) | GRIN2B | |
| SCHEMBL23055669 | 0.83 | GRIN2B (0.39) | GRIN2B | |
| Hydrochloric Acid SCHEMBL28926964 | 0.82 | GRIN2B (0.38) | GRIN2B | |
| SCHEMBL29974035 | 0.76 | PTPN11 (0.34) | HCRTR1HCRTR2PTPN11MAPK3MAPK1 | |
| Hydrochloric Acid SCHEMBL23045212 | 0.75 | PTPN11 (0.34) | HCRTR1HCRTR2PTPN11MAPK3MAPK1 | |
| SCHEMBL23055345 | 0.71 | KMO (0.46) | GRIN2B | |
| SCHEMBL23639174 | 0.69 | CKS1B (0.39) | GRIN2B | |
| SCHEMBL30329127 | 0.68 | GRIN2B (0.38) | GRIN2B | |
| SCHEMBL23055614 | 0.68 | GRIN2B (0.41) | GRIN2B | |
| SCHEMBL25164102 | 0.68 | HRH4 (0.35) | GRIN2BPTPN11MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| CN-115397467-A | Therapeutic agent for tauopathy | 住友制药株式会社 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021141041-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | 大日本住友製薬株式会社 | 2021-07-15 | — | — | WO | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | GRIN2B 441/4885HCRTR1 2721/4885HCRTR2 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.